Also known as: severe hypoglycemia
C-peptide is described as a key biomarker for beta cell function in type 1 diabetes and a potential surrogate endpoint for drug approval. Current trial endpoints remain difficult for disease-modifying therapies.
A multicenter retrospective cohort study of 17 patients with type 2 diabetes and end-stage renal disease found injectable semaglutide was associated with descriptive changes in glycemic control and body weight. No cardiovascular deaths, nonfatal myocardial infarctions, or nonfatal strokes were observed during follow-up.
The congenital hyperinsulinism pipeline includes 4+ active companies and 4+ therapies across clinical and nonclinical stages. Zealand Pharma advanced dasiglucagon in January 2026, while RZ358 is in Phase III evaluation.
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
Recent research explores outcomes when patients stop GLP-1 medications and finds pharmacist-led interventions can help older adults avoid dangerous low blood sugar episodes.
Xenetic Biosciences reported a net loss of $2.7 million for 2025 while advancing its DNase-based cancer therapy toward clinical trials, ending the year with $7.9 million in cash. Xeris Biopharma will announce its 2025 financial results on March 2, 2026.
Amylyx Pharmaceuticals is advancing avexitide toward potential FDA approval for post-bariatric hypoglycemia, with Phase 3 LUCIDITY trial results expected in Q3 2026 and a cash runway extending into 2028.
Study of 3600 older adults with type 1 diabetes across US and European registries reveals significant gaps in guideline-recommended cardiovascular therapies and diabetes technology use despite high disease burden.
GLP-1 receptor agonists like semaglutide and liraglutide may improve fertility through metabolic benefits but are not recommended during pregnancy. Current guidance advises discontinuing long-acting agents at least two months before conception.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07375615 |
Continous Glucose Monitoring in Neonates at Risk of Hypoglycaemia- a Feasibility Study |
COMPLETED | |
| NCT07329985 |
FEAR of HYPOGLYCEMIA in PATIENTS WITH DIABETES |
NOT_YET_RECRUITING | |
| NCT07286500 |
"Sexual Activity and Hypoglycemia Risk in Adults With Type 1 or Type 2 Diabetes Using Insulin Therapy and Continuous Glucose Monitoring" |
RECRUITING | |
| NCT07233421 |
Frequency of Hypoglycemia in Children With Beta-blocker Treated Long QT-syndrome |
ENROLLING_BY_INVITATION | NA |
| NCT07132476 |
The Construction and Validation of a Risk Prediction Model for Perioperative Hypoglycemia in Digestive Endoscopy |
COMPLETED | |
| NCT07082478 |
External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia |
RECRUITING | |
| NCT06986603 |
Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT06893341 |
Monitoring Exhaled Breath to Noninvasively Detect Glycemic Events |
RECRUITING | NA |
| NCT06657287 |
Postprandial Hypotension and Insulin Levels |
COMPLETED | |
| NCT06652867 |
Hypoglycemia Biomarkers to Predict Timing of a Hypoglycemic Event |
COMPLETED |
